Dublin, Ireland (PRWEB) June 13, 2013
Dignity Sciences Ltd, a privately held biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application serial number 13/318,290, entitled "Use of PUFAs for Treating Skin Inflammation." The application has allowed claims that provide Dignity Sciences exclusivity for topical compositions of its lead compound DS107 as well as the early stage follow-on compound DS109. In addition, the allowed claims provide exclusivity for methods of using these compositions.
Dignity Sciences believes the allowance of this patent confirms the novelty of its approach to treating skin ailments. With many of its important patents coming into fruition, the company looks forward to justifying its development strategy with data from the ongoing research programs.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The granted patent will provide DS107E, DS109A and other Dignity Sciences’ compositions, exclusivity into 2030.
DS107E is a topical formulation of a semi-synthetic derivative of dihomo-gamma linolenic acid, an omega-6 fatty acid. DS107E is currently being developed as an advanced therapy for treating skin diseases.
About Dignity Sciences
Dignity Sciences, a privately held biopharmaceutical company, was established to discover and develop scientifically innovative healthcare solutions that improve the quality of life of people with diseases for which current therapies are unsatisfactory. Dignity Sciences is led by recognized experts in developing omega-6 and omega-3 fatty acids, including their bioactive derivatives, for the treatment of human disease.